p53 is dynamically involved in the core of the EV biogenesis pathway, and TP53 mutations not only abrogate this effect directly or indirectly via a dominant-negative action, but they even exert additional gain-of-function activities that further favor tumor progression. This evidence concerns the gene TP53 and neoplasm.